CHRS - Coherus BioSciences, Inc.
| Previous Close | 9.98 |
| Open | 9.92 |
| Bid | 8.25 x 900 |
| Ask | 12.00 x 1100 |
| Day's Range | 9.72 - 10.05 |
| 52 Week Range | 8.55 - 20.66 |
| Volume | 652,164 |
| Avg. Volume | 758,296 |
| Market Cap | 661.883M |
| Beta (3Y Monthly) | 4.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.23 |
| Earnings Date | Mar 6, 2019 - Mar 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.00 |
- Thomson Reuters StreetEvents•2 days ago
Edited Transcript of CHRS earnings conference call or presentation 10-May-18 8:30pm GMT
Q1 2018 Coherus BioSciences Inc Earnings Call
- Insider Monkey•3 days ago
Should You Buy Coherus Biosciences Inc (CHRS)?
Amid an overall market correction, many stocks that smart money investors were collectively bullish on tanked during the fourth quarter. Among them, Amazon and Netflix ranked among the top 30 picks and both lost around 20%. Facebook, which was the second most popular stock, lost 14% amid uncertainty regarding the interest rates and tech valuations. […]
Markit•9 days agoSee what the IHS Markit Score report has to say about Coherus BioSciences Inc.
Coherus BioSciences Inc NASDAQ NMS:CHRS
- GlobeNewswire•12 days ago
Investor Expectations to Drive Momentum within Virtu Financial, Fate Therapeutics, Tandem Diabetes Care, Eli Lilly, Griffon, and Coherus BioSciences — Discovering Underlying Factors of Influence
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•15 days ago
Coherus BioSciences Announces Apexus Contract Agreement for 340B Hospitals and Clinics, and Q-Code Issuance from CMS
REDWOOD CITY, Calif., Nov. 30, 2018 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that the company has executed a 340B prime vendor program contract agreement.
- Zacks•16 days ago
Coherus BioSciences (CHRS): Moving Average Crossover Alert
Coherus BioSciences, Inc. (CHRS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
- GlobeNewswire•17 days ago
Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Nov. 27, 2018 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective November 14, 2018, the compensation committee of the company’s.
Markit•21 days agoSee what the IHS Markit Score report has to say about Coherus BioSciences Inc.
This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on November 8. Index (PMI) data, output in the Healthcare sector is rising.
- Simply Wall St.•29 days ago
Is Coherus BioSciences Inc’s (NASDAQ:CHRS) CEO Paid Enough Relative To Peers?
Denny Lanfear became the CEO of Coherus BioSciences Inc (NASDAQ:CHRS) in 2010. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...
Markit•last monthSee what the IHS Markit Score report has to say about Coherus BioSciences Inc.
Coherus BioSciences Inc NASDAQ NMS:CHRS
- GlobeNewswire•last month
Coherus BioSciences Management to Present at the 27th Annual Credit Suisse Healthcare Conference
REDWOOD CITY, Calif., Nov. 12, 2018 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will be presenting at the 27th Annual Credit Suisse.
- Reuters•last month
Coherus prices biosimilar to Amgen's Neulasta at 33 pct discount
Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc's infection-fighting treatment, Neulasta, at a 33 percent discount. The list price of $4,175 per unit set by Coherus is the same as Mylan NV's biosimilar Fulphila that was approved earlier this year. Coherus intends to launch the biosimilar, Udenyca, on Jan. 3, it said on a conference call.
- Associated Press•last month
Coherus BioSciences: 3Q Earnings Snapshot
On a per-share basis, the Redwood City, California-based company said it had a loss of 87 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
- GlobeNewswire•last month
Coherus BioSciences Reports Corporate Highlights and Third Quarter 2018 Financial Results
REDWOOD CITY, Calif., Nov. 08, 2018 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today reviewed corporate highlights and reported financial results for the quarter ended.
Markit•last monthSee what the IHS Markit Score report has to say about Coherus BioSciences Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Markit•2 months agoSee what the IHS Markit Score report has to say about Coherus BioSciences Inc.
Coherus BioSciences Inc NASDAQ NMS:CHRS
- GlobeNewswire•2 months ago
Coherus BioSciences to Report Third Quarter 2018 Financial Results on November 8th
REDWOOD CITY, Calif., Oct. 22, 2018 -- Coherus BioSciences, Inc. (Nasdaq: CHRS) today announced that its third quarter 2018 financial results will be released after market.
- Motley Fool•2 months ago
Here's Why Coherus BioSciences Fell 18.1% in September
Enthusiasm for the biopharma is wearing off despite its announcement of an important commercial milestone.
- GlobeNewswire•2 months ago
Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Oct. 09, 2018 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective October 8, 2018, the compensation committee of the company’s.
Market Realist•2 months agoMylan’s Biosimilar of Neulasta Expected to Be a Key Growth Driver
Why Are Wall Street Analysts Bullish on Mylan Stock? Mylan’s (MYL) Fulphila (pegfilgrastim), a biosimilar of Amgen’s (AMGN) Neulasta, received a positive CHMP (Committee for Medicinal Products for Human Use) opinion on September 21. Two other Neulasta biosimilars—Cinfa Biotech’s Pelmeg and Sandoz’s Ziextenzo—also received a positive CHMP opinion on September 21.
GuruFocus.com•3 months agoAmgen's Neulasta Has a New Competitor in Europe
Amgen Inc. (AMGN) has not been affected by the decision of the European Commission to approve Coherus BioSciences' (CHRS) UDENYCA for commercialization in Europe. UDENYCA, one of the first pegfilgrastim products to gain the European marketing authorization, is a biosimilar of Amgen's Neulasta. Warning! GuruFocus has detected 1 Warning Sign with FB.
- GlobeNewswire•3 months ago
Coherus BioSciences Receives European Commission Approval for UDENYCA™ (Pegfilgrastim Biosimilar)
Coherus BioSciences, Inc. (CHRS), today announced the European Commission (EC) has granted marketing authorization to UDENYCA™ (formerly CHS-1701), a pegfilgrastim (Neulasta®) biosimilar. UDENYCA™ is one of the first pegfilgrastim biosimilars to gain marketing authorization in Europe. "Today’s EC approval decision is the first marketing authorization for Coherus, an important step forward in realizing our mission of increasing access to biologic treatments to patients globally,” said Denny Lanfear, President and CEO of Coherus BioSciences.
Markit•3 months agoSee what the IHS Markit Score report has to say about Coherus BioSciences Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding CHRS is favorable, with net inflows of $5.07 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing.
